JOURNAL ARTICLE

Forced vital capacity in idiopathic pulmonary fibrosis—FDA review of pirfenidone and nintedanib

Banu A Karimi-Shah, Badrul A Chowdhury
New England Journal of Medicine 2015 March 26, 372 (13): 1189-91
25806913
Idiopathic pulmonary fibrosis (IPF) is a devastating disease of unknown cause, and for years the only effective treatment available was lung transplantation. In October 2014, two drugs became available in the United States for patients with IPF when the Food and Drug Administration (FDA) approved..

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
25806913
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"